- Home
- PBYI vs ENLV Comparison
PBYI vs ENLV Comparison
Compare PBYI & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PBYI | ENLV |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.4M | 246.9M |
| IPO Year | 2011 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PBYI | ENLV |
|---|---|---|
| Price | $6.00 | $1.09 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 429.2K | 198.8K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $27,685,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.58 | $0.66 |
| 52 Week High | $7.68 | $2.10 |
Technical Indicators
Market Signals| Indicator | PBYI | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 42.49 | 48.35 |
| Support Level | $5.57 | $1.00 |
| Resistance Level | $6.15 | $1.23 |
| Average True Range (ATR) | 0.37 | 0.06 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 33.18 | 29.37 |
Price Performance
Historical ComparisonAbout PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.